Skip to Content
Print Share

Erenumab Approval Status

Erenumab is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide (CGRP) in development for the prevention of episodic and chronic migraine.

Development Status and FDA Approval Process for erenumab

DateArticle
May 18, 2017Amgen Submits Biologics License Application to the FDA for Erenumab
Nov 16, 2016Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study
Sep 28, 2016Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study
Sep 15, 2016Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine
Jun  8, 2016Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine
May 15, 2015Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide